Safdarjung first hospital to introduce stereotactic tumor treatment to India
Delhi´s Safdarjung Hospital is the first clinic in India to use an innovative navigation system for minimally invasive treatments. The system, designed by Swiss medtech company CAScination AG, was used in April to successfully treat the first patients. “We rely on the most advanced technology available on the market to perform minimally invasive procedures at our hospital,” says Prof Dr Shabnam Bhandari Grover, Department of Radiology and Imaging, Safdarjung Hospital.
At Safdarjung, a government hospital, demand for minimally invasive treatment is growing. In June it opened a new emergency annex to help meet that demand. Dr Grover and her team expect to perform over 200 stereotactic ablation treatments per year in the newly built annex, equipped with the latest technology. “We are very happy to be part of this ambitious project and are convinced that Safdarjung will play a leading role in introducing CAScination’s high-accuracy ablation treatment to the whole of India,” says Matthias Peterhans, CEO CAScination AG.
About 25 senior staff of the Department of Radiology and Imaging at Safdarjung Hospital attended the extended practical trainings provided by CAScination AG in April in Delhi. CAScination AG CEO Matthias Peterhans, who can look back on a decade of experience in minimally invasive treatments with CAScination technology, trained the senior hospital staff during various trainings. After the trainings the acquired knowledge was put into practice and the first patients in India were treated successfully with CAS-One IR.
CAScination’s CAS-One IR is now in the newly opened emergency block at Safdarjung Hospital. With the addition of almost 260 beds, 37 intensive care unit (ICU) beds and six operation theatres the new emergency block makes Safdarjung Hospital one of the largest public facilities in India. The total capacity of 1,840 beds ranks Safdarjung Hospital among the largest government hospitals in India, providing health care services to a growing number of patients in Delhi who need treatment.
“Both the public and the private market for healthcare in India are very dynamic. We see great potential for CAScination’s technology, that is renowned for its safety and reliability. We are planning to expand our presence here with more installations in the near future,” says Rajavel Subramanian, Vice President Sales-India at CAScination AG.
CAS-One IR is a navigation system for minimally invasive treatment of cancer tumors in the liver, lung, kidney, pancreas and bones. For patients, as well as for practitioners, the gentle treatment with CAScination technology offers some crucial benefits: Image fusion capabilities enlarge treatment planning and provide a quality control directly after the ablation, aiming to reduce the amount of local recurrences. Compared to conventional surgery, the post-operative stay in hospital is shortened and recovery is faster.
CAScination AG is an award-winning medical technology company dedicated to the development, manufacturing and commercialization of innovations in computer-assisted and image-guided surgery. Our trailblazing navigation systems and surgical robots are designed to improve outcomes for patients undergoing surgical or interventional procedures and offer new perspectives to patients worldwide. Our CAS-One planning and navigation system is used to treat patients suffering from soft tissue cancer (e.g. liver cancer) by many hospitals across Europe, and we are developing further applications in a number of disease areas.
Fon + 41 (0) 31 552 0440
PRESS RELEASE FIRST CASES IN INDIA